A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available (Q38184218)

30 August 2017

A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available (English)

1 reference

30 August 2017

Tomohiro Ishikawa

1

1 reference

30 August 2017

Atsushi Yamanaka

series ordinal

2

1 reference

30 August 2017

Eiji Konishi

series ordinal

3

1 reference

30 August 2017

language of work or name

English

0 references

publication date

29 January 2014

1 reference

30 August 2017

1 reference

30 August 2017

32

1 reference

30 August 2017

1326-1337

1 reference

30 August 2017

12

1 reference

Neuroinvasive flavivirus infections

30 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Current status of flavivirus vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Immunoprophylaxis against important virus disease of horses, farm animals and birds

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Immunity and immune response, pathology and pathologic changes: progress and challenges in the immunopathology of yellow fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Yellow Fever: 100 Years of Discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

The use of yellow fever virus modified by in vitro cultivation for human immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Comparison of the immunogenicity and safety of two 17D yellow fever vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Adverse event reports following yellow fever vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Hepatitis and death following vaccination with 17D-204 yellow fever vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

An inactivated cell-culture vaccine against yellow fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Ecologic studies of Japanese encephalitis virus in Japan. VI. Swine infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Ecology and geographical expansion of Japanese encephalitis virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Past, Present, and Future of Japanese Encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Estimated global incidence of Japanese encephalitis: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Protection against Japanese encephalitis by inactivated vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: a randomized, observer-blind, controlled Phase 3 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Safety profile of the Vero cell-derived Japanese encephalitis virus (JEV) vaccine IXIARO(®).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Immunogenicity and safety of IXIARO (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Superior immunogenicity of a freeze-dried, cell culture-derived Japanese encephalitis vaccine (inactivated).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Safety and immunogenicity of a freeze-dried, cell culture-derived Japanese encephalitis vaccine (Inactivated) (JEBIK(®)V) in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Non-clinical and phase I clinical trials of a Vero cell-derived inactivated Japanese encephalitis vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Current use and development of vaccines for Japanese encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO/CVI meeting, Bangkok, Thailand, 13-15 October 1998.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Safety and immunogenicity of a single administration of live-attenuated Japanese encephalitis vaccine in previously primed 2- to 5-year-olds and naive 12- to 24-month-olds: multicenter randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: Randomised controlled phase 3 trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12-18 months: randomized, controlled phase 3 immunogenicity and safety trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Emergence of genotype I of Japanese encephalitis virus as the dominant genotype in Asia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Cross-protective capacity of Japanese encephalitis (JE) vaccines against circulating heterologous JE virus genotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Epidemiology of tick-borne encephalitis (TBE) in Europe and its prevention by available vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Tick-borne encephalitis virus - a review of an emerging zoonosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Tick-borne encephalitis: the impact of epidemiology, changing lifestyle, and environmental factors. Conference report of the 12th Annual Meeting of the International Scientific Working Group on Tick-Borne Encephalitis (ISW-TBE).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Albumin is a necessary stabilizer of TBE-vaccine to avoid fever in children after vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Vaccines for preventing tick-borne encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Prevention of tick-borne encephalitis by FSME-IMMUN vaccines: review of a clinical development programme.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Safety, immunogenicity and tolerability of a new pediatric tick-borne encephalitis (TBE) vaccine, free of protein-derived stabilizer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Clinical evaluation of a polygeline-free tick-borne encephalitis vaccine for adolescents and adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Long-term persistence of tick-borne encephalitis antibodies in adults 5 years after booster vaccination with Encepur Adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Long-term persistence of tick-borne encephalitis antibodies in children 5 years after first booster vaccination with Encepur Children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Characterization of neutralizing antibodies to Far Eastern of tick-borne encephalitis virus subtype and the antibody avidity for four tick-borne encephalitis vaccines in human

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Vaccination and tick-borne encephalitis, central Europe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Quantitative comparison of the cross-protection induced by tick-borne encephalitis virus vaccines based on European and Far Eastern virus subtypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

A tick-borne encephalitis virus vaccine based on the European prototype strain induces broadly reactive cross-neutralizing antibodies in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Fever from the forest: prospects for the continued emergence of sylvatic dengue virus and its impact on public health

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Dengue and dengue hemorrhagic fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

The global distribution and burden of dengue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Neutralization and antibody-dependent enhancement of dengue viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Research on dengue during World War II

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Scientific consultation on immunological correlates of protection induced by dengue vaccines report from a meeting held at the World Health Organization 17-18 November 2005.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Immunogenicity and protective efficacy of a vaxfectin-adjuvanted tetravalent dengue DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Dengue vaccine development: a 75% solution?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Dengue vaccine efficacy trial: does interference cause failure?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Challenges in the interpretation of dengue vaccine trial results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2-11 years in Malaysia: a randomized, placebo-controlled, Phase III study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

An automated Dengue virus microneutralization plaque assay performed in human Fc{gamma} receptor-expressing CV-1 cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Dengue virus infection-enhancing activity in serum samples with neutralizing activity as determined by using FcγR-expressing cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Manipulation of immunodominant dengue virus E protein epitopes reduces potential antibody-dependent enhancement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Sculpting humoral immunity through dengue vaccination to enhance protective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Mouse models of dengue virus infection and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Common marmoset (Callithrix jacchus) as a primate model of dengue virus infection: development of high levels of viraemia and demonstration of protective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

The dengue human challenge model: has the time come to accept this challenge?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Transmission dynamics and changing epidemiology of West Nile virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

The zoonotic flaviviruses of southern, south-eastern and eastern Asia, and Australasia: the potential for emergent viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

The virology, epidemiology, and clinical impact of West Nile virus: a decade of advancements in research since its introduction into the Western Hemisphere

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

West Nile virus: recent trends in diagnosis and vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Recent progress in West Nile virus diagnosis and vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Phase II, dose ranging study of the safety and immunogenicity of single dose West Nile vaccine in healthy adults ≥ 50 years of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

The live attenuated chimeric vaccine rWN/DEN4Δ30 is well-tolerated and immunogenic in healthy flavivirus-naïve adult volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Immunogenicity and Protective Efficacy of a Recombinant Subunit West Nile Virus Vaccine in Rhesus Monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Cost-effectiveness of West Nile virus vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

Tick-borne encephalitis in Europe, 2007 to 2009.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.040

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2014.01.040

1 reference

30 August 2017

1 reference